Denali Therapeutics Inc.

Cathal S Mahon

Mihalis S Kariolis

Adam P Silverman

Ankita Srivastava

Anastasia Henry

Mark S Dennis

Gunasekaran Kannan

Rachel Prorok

Kathryn M Monroe

Bettina Van Lengerich

Joshua I Park

Hanh Giai Ngo

Yashas Rajendra

Tianao Yuan

Julie Ullman

Tina Giese

Zhenyu Gu

Shrishti Tyagi

Melina Lenser

Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise an acid alpha-glucosidase (GAA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat Pompe disease.

Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.

Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.

Fusion proteins comprising enzyme replacement therapy enzymes

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

Anti-TREM2 antibodies and methods of use thereof

Growing community of inventors

South San Francisco, CA, United States of America

Cathal S Mahon